







## Adult Community IV Antibiotic Treatment: Authorisation to Administer and Administration Record: Flucloxacillin 8g elastomeric pump

Patient details					Aller	Allergies & Intolerances:				Indication for treatment:													
Name																							
Address																							
						1					Date antibiotic to start in community:												
NHS number																							
DOB				No known allergies					Planned treatment length in community or end date:														
				Document nature, details and date of																			
					each reaction																		
eGFR:				eatinine:		Date:				Weight (kg): Date:													
Medication				Dose		Frequency				Instructions for preparation and use							Ph	armacy					
																				(	check		
Flucloxacillin				8g		Continuous		IV Ad		Administration:													
(unlicensed)			(in 23	0mL Bax	ter	infusion	over		Conn	onnect the elastomeric device as per guidelines.													
,			LV10 €	elastome	eric	ic 24 hours		0		Once connected the elastomeric device is designed to administer the dose by continuous									us				
				evice)					infusion over 24 hours														
			Flush PICC line with 10mL sodium chloride 0.9% before each dose and at the end of the treatment course																				
Sodium Chloride 0.9%																							
Date &	Date &					$\overline{A}$																	
time:																							
									/		/					/							
Given by:		/		<i>'</i>	/		1	<del>-  </del>		/			ľ	<u> </u>	<del>                                     </del>	<u> </u>	<u>/</u>	/	ľ	ľ	ľ		
•																							
						·					· · · · · · · · · · · · · · · · · · ·												
Prescriber	must be F2	or abov	e, or a su	itable no	on-medi	ical preso	riber.																
Signed:					Na	Name:					ofessional				Bleep/		Date:						
				(Print	(Print Name)					registration			Telephone:										
										nu	mber:												

Author: Andrea Hackett (Lead Technician OPAT)
Check by Nathalie Roberts (OPAT Pharmacist)
Authorised by Medicine Governance Group

Review date: June 2025

Version 02

Approval date: June 2023







Author: Andrea Hackett (Lead Technician OPAT) Check by Nathalie Roberts (OPAT Pharmacist) Authorised by Medicine Governance Group Review date: June 2025

Version 02

Approval date: June 2023